Maravai LifeSciences Holdings Future Growth
Future criteria checks 1/6
Maravai LifeSciences Holdings is forecast to grow earnings and revenue by 117.7% and 10.3% per annum respectively. EPS is expected to grow by 104.1% per annum. Return on equity is forecast to be 0.09% in 3 years.
Key information
117.7%
Earnings growth rate
104.1%
EPS growth rate
Life Sciences earnings growth | 22.5% |
Revenue growth rate | 10.3% |
Future return on equity | 0.09% |
Analyst coverage | Good |
Last updated | 22 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 350 | -17 | N/A | 27 | 8 |
12/31/2025 | 303 | -7 | 64 | 69 | 13 |
12/31/2024 | 276 | -28 | 23 | 42 | 13 |
3/31/2024 | 274 | -131 | -31 | 33 | N/A |
12/31/2023 | 289 | -119 | 61 | 126 | N/A |
9/30/2023 | 420 | 25 | 163 | 218 | N/A |
6/30/2023 | 544 | 75 | 268 | 314 | N/A |
3/31/2023 | 718 | 153 | 437 | 459 | N/A |
12/31/2022 | 883 | 220 | 519 | 536 | N/A |
9/30/2022 | 907 | 238 | 479 | 495 | N/A |
6/30/2022 | 920 | 248 | 479 | 491 | N/A |
3/31/2022 | 895 | 226 | 478 | 493 | N/A |
12/31/2021 | 799 | 182 | 354 | 369 | N/A |
9/30/2021 | 669 | 150 | 371 | 389 | N/A |
6/30/2021 | 552 | 127 | 308 | 335 | N/A |
3/31/2021 | 381 | 78 | 155 | 181 | N/A |
12/31/2020 | 284 | 77 | 127 | 152 | N/A |
12/31/2019 | 143 | -8 | 7 | 24 | N/A |
12/31/2018 | 124 | -18 | -4 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MAR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MAR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MAR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MAR's revenue (10.3% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: MAR's revenue (10.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MAR's Return on Equity is forecast to be low in 3 years time (0.1%).